Factory Solutions Services & Capabilities
- Facility design
- Product feasibility studies
- Process design, optimization, and scale-up
- Regulatory review and support
- Technology transfer
Factory Solutions are rooted in iBio's guiding philosophy of empowering companies to fully capitalize on the advantages of FastPharming – iBio’s proprietary approach to plant-made pharmaceutical (PMP) production. Our team is comprised of PMP experts who fully understand the science behind our technology and are experts in the design and construction of PMP facilities, including the demands of operating a hydroponic facility within a cGMP environment.
Factory Solutions clients typically start their journey with iBio as CDMO customers. By closely collaborating on product development and processes within the iBio facility, the process development team can fully apply Quality-by-Design approaches, perfect processes, and design your facility with a complete understanding your needs.
By being directly hands-on with the products and processes within the iBio facility, the development team can quickly adapt what is learned during the feasibility and process development stages. Not only can your specific product, process, and facility design be perfected, your path to the clinic can begin while your facility is being designed and built.
iBio offers extensive training and complete transfer of process design and Quality Management Systems, allowing you to quickly move into production upon the completion of your facility.
CC Pharming utilized iBio’s Factory Solutions to design and build an 8,000+ square foot pilot in Beijing. With the pilot plant completed, the design of a large-scale facility is now underway.
CC Pharming specializes in biomedical technology research and product development. They are an innovative company utilizing plant bioreactor technology and are focusing on plant molecular medicine technology, research, and product development.
This collaboration offers CC Pharming the opportunity to further its leadership position within the increasingly competitive Chinese market and gives iBio a strong foothold in the world’s second largest pharmaceutical market.